3Drinka PJ.The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency.J Am Med Dir Assoc,2004,5:382-386.
4Gur A,Colpan L,Cevik R,et al.Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.Clin Biochem,2005,38:66-72.
5Nuti R,Martini G,Valenti R,et al.Vitamin D status and bone turnover in women with a cute hip fracture.Clin Orthop Relat Res,2004,422:208-213.
6Garnero P,Delmas PD.Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metablic bone disease.J Clin Endocrinol Metab,1993,77:1046-1053.
7Davey RA,Morris HA.Effects of dihydrotestrone on osteoblast gene expression in osteopenic ovariectomized rats.Endocr Res,2004,30:361-368.
8Ivaska KK,Kakonen SM,Gerdhem P,et al.Urinary Osteocalcin as a Marker of Bone Metabolism.Clin Chem,2005,51:618-628.
9Akesson K,Kakonen SM,Josefsson PO,et al.Fracture-induced changes in bone turnover:a potential confounder in the use of biochemical markers in osteoporosis.J Bone Miner Metab,2005,23:30-35.
10Scariano JK,Garry P J,Montoya GD,et al.Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide(PINP) measurements for identifying elderly women with decreased bone mineral density.Scand J Clin Lab Invest,2002,62:237-243.
4[1]NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. JAMA 2001,285:785-795.
5[2]Weinstein RS. True strength. J Bone Miner Res 2000,15:621-625.
6[3]Chesnut Ⅲ CH, Rosen CJ for the Bone Quality Discussion Group. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001,16:2163-2172.
7[4]Marcus R, Wong M, Heath Ⅲ H, et al. Antiresorptive treatment of posrmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002,23:16-37.
8[5]Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001,19:331-337.
9[6]Cummings SR, Karpf DB, Harris F, et al. Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002,112: 282-289.
10[7]Heaney RP. Is the paradigm shifting? Bone 2003,33:457-465.
